Recently, the National Healthcare Security Administration officially issued a notice, organizing provincial-level medical insurance departments to conduct collective interviews with the principal responsible persons of all designated medical institutions for mental disorders within their jurisdictions. This initiative aims to further strengthen the management of medical insurance funds in the field of mental disorder diagnosis and treatment, crack down on illegal activities such as inducing hospitalization, fraudulent hospitalization, fabricated diagnoses, and irregular charges, while enhancing the compliance awareness of medical institutions and fortifying the healthcare security network for patients with mental disorders, ensuring that medical insurance funds are truly used where they are most needed. This special campaign not only marks a new height of national emphasis on mental health, but also sets higher requirements for the compliant and high-quality supply of psychotropic drugs. As the source of clinical medication, the quality and compliance of psychotropic active pharmaceutical ingredients (APIs) directly relate to the rationality of medical insurance fund utilization. Our company's core psychotropic API, quetiapine fumarate, precisely aligns with the policy orientation conveyed by this interview, providing solid support for downstream formulation production and standardized clinical medication, thereby facilitating the effective implementation of medical insurance policies.
Since 2026, severe mental disorders have been incorporated into the unified management of 62 chronic and special diseases, with a significant increase in reimbursement rates. Multiple antipsychotic drugs have been included in the national centralized procurement, achieving an average price reduction exceeding 50%. A series of policies have established a dual system of "regulation + protection," which not only safeguards the safety baseline of medical insurance funds but also effectively alleviates the medication burden on patients. All of this is inseparable from the stable supply of high-quality psychiatric active pharmaceutical ingredients (APIs). Only with qualified APIs and orderly supply can downstream formulations be produced in compliance and used clinically in a standardized manner, thereby truly realizing the policy objective of benefiting the public through medical insurance.
As a core active pharmaceutical ingredient (API) in the field of psychiatric treatment, our company's authorized sales of quetiapine fumarate aligns perfectly with the dual policy orientation of "regulation + protection" in the current medical insurance system, serving as a pivotal product to support standardized clinical diagnosis and treatment. This product, as a key raw material for downstream antipsychotic preparations, is widely used in the treatment of common psychiatric disorders such as schizophrenia and bipolar disorder. Both of these conditions fall under the category of severe mental illnesses included in the management of chronic and special diseases. The quality stability and purity compliance rate of these drugs not only directly impact the safety and efficacy of clinical medication but also significantly influence the rational use of medical insurance funds. High-quality APIs can prevent ineffective or repeated medication due to substandard preparation quality, thereby reducing fund wastage at the source and aligning with the core requirement of "standardizing the use of medical insurance funds" as emphasized in the regulatory discussions. Leveraging India's advanced production processes and stringent quality control systems, our quetiapine fumarate can stably meet the large-scale production demands of downstream pharmaceutical manufacturers, helping to reduce preparation production costs. This precisely responds to national policies on centralized procurement price reductions and improving drug accessibility, providing psychiatric patients with cost-effective treatment options. It also offers solid support for downstream manufacturers to comply with medical insurance designated diagnosis and treatment requirements and meet regulatory standards. At the beginning of 2026, we have achieved a new breakthrough in pricing—excellent! We warmly invite industry leaders to establish long-term strategic partnerships with our company to jointly strengthen the quality and safety safeguards for psychiatric medications.